drugset / Trial / NCT07155668
A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a clinical trial assessing the safety, tolerability and pharmacokinetics (PK) of an investigational drug, VRDN-003, in participants with TED (Thyroid Eye Disease)
Timeline
- Start
- 2025-07-01
- Primary completion
- 2026-05-28
- Completion
- 2026-05-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | VRDN-003 | Monoclonal antibody | 300 mg | Subcutaneous |